statins

Browse trials
V2  
List  

treatment    comparator  All cause death Coronary death Coronary event Adverse events Cardiovascular death Death from cancer MACE Fatal MI Revascularization Haemmorhagic stroke Fatal stroke Non fatal stroke Non fatal MI Cancer Rhabdomyolysis Non vascular death stroke (fatal and non fatal)  myocardial infarction (fatal and non fatal)  cardiac death cardiovascular events Coronary death and non fatal MI Myopathy LDL non cardiovascular death  Venous thromboembolism new-onset diabetes  MI (CK-MB >3x ULN at 6 and 12 hours after PCI) MI (troponin I >3x ULN at 6 and 12 hours after PCI) total cholesterol (at 1 y) HDL (at 1 y)     
Fluvastatincardiovascular prevention, in secondary prevention vs placeboNSNS by 33% ---NS-----NS-NS---NS-NS--NS------
Fluvastatincardiovascular prevention, in primary prevention vs placeboNS-----------------NS----NS------
Fluvastatincardiovascular prevention, in hypertensive patients vs placeboNS------------------NS----------
Fluvastatinpercutaneous coronary intervention, in all type of patients vs placeboNS---NS---NS---NS---NS-------------
Atorvastatincardiovascular prevention, in secondary prevention vs placebo------------------------------
Atorvastatincardiovascular prevention, in secondary prevention vs usual care by 43% - by 51% ------NSNS---NS--- by 43% ----NS------
Atorvastatincardiovascular prevention, in secondary prevention vs angioplasty-NS----NS-----NS---NS-NSNS----------
Atorvastatincardiovascular prevention, in secondary prevention vs atorvastatinNSNS by 20% by 36% -----NS-- by 21% -NS- by 24% -- by 21% [demonstrated] by 20% by 568% --------
Atorvastatincardiovascular prevention, in secondary prevention vs lovastatinNS-----NS---------NS---NS---------
Atorvastatincardiovascular prevention, in secondary prevention vs pravastatin by 67% NS-NSNSNSNS-----NS-NS-NS---NSNS-NS------
Atorvastatincardiovascular prevention, in secondary prevention vs simvastatinNSNSNS by 130% -NS------ by 17% -NS-NS---NS by 802% --------
Atorvastatincardiovascular prevention, in diabetic patients vs placeboNSNS by 31% NSNSNS by 20% [demonstrated]--NSNS- by 40% -NS-NS-- by 19% -NS--------
Atorvastatincardiovascular prevention, in hypertensive patients vs placeboNS- by 28% [demonstrated]-NS- by 20% -------NS- by 27% --- by 35% --NS-NS----
Atorvastatinheart failure, in all type of patients vs controlNS---NS-------------------------
Atorvastatinheart failure, in all type of patients vs placeboNS-----------------------------
Atorvastatinpercutaneous coronary intervention, in all type of patients vs control-------------------------- by 44% by 44% --
Atorvastatinpercutaneous coronary intervention, in all type of patients vs placeboNS----- by 61% -NS--- by 64% --- by 71% -------------
Atorvastatinpercutaneous coronary intervention, in all type of patients vs usual careNS---NS---NS---NS---NS-------------
Cerivastatinheart failure, in all type of patients vs placebo------------------------------
Lovastatincardiovascular prevention, in secondary prevention vs placeboNSNS by 24% [demonstrated]-NS-------NS-NS-NS-NS- by 24% --NS-NS----
Lovastatincardiovascular prevention, in secondary prevention vs usual careNSNS----------NS-----NS----NS------
Lovastatincardiovascular prevention, in diabetic patients vs placebo------------------------------
Pravastatincardiovascular prevention, in secondary prevention vs placebo by 15% by 21% [demonstrated] by 22% [demonstrated]- by 21% NS by 18% --NSNS- by 14% -NS- by 13% -NS by 17% [demonstrated] by 22% NS-NS-NS----
Pravastatincardiovascular prevention, in secondary prevention vs usual careNS---------NS-----NS--NS---NS-NS----
Pravastatincardiovascular prevention, in hypertensive patients vs usual careNSNSNS-NSNS----NS--NS--NS-NSNSNS--NS-NS----
Pravastatincardiovascular prevention, in primary prevention vs controlNS by 47% by 33% -NS- by 30% --NS--NS---NS-- by 25% ---NS-NS----
Pravastatincardiovascular prevention, in primary prevention vs placeboNSNS by 23% [demonstrated]- by 32% NS----NS- by 30% -NS-NS-NS by 41% by 30% --NS-NS----
Pravastatincardiovascular prevention, in primary prevention vs usual care------------------------------
Pravastatincardiovascular prevention, in diabetic patients vs placebo------------------------------
Pravastatinpercutaneous coronary intervention, in all type of patients vs placeboNS---NS---NS---NS---NS-------------
Rosuvastatincardiovascular prevention, in diabetic patients vs placeboNSNS--NS-------------------------
Rosuvastatincardiovascular prevention, in primary prevention vs placebo by 12% - by 35% -NS- by 32% [demonstrated]--NSNS- by 65% --- by 37% - by 26% by 32% [demonstrated] by 35% --- by 43% NS----
Rosuvastatinheart failure, in all type of patients vs placeboNS-NS-NS--NS--NSNSNS--NSNSNS-NS-----NS----
Simvastatincardiovascular prevention, in secondary prevention vs placebo by 15% [demonstrated] by 22% by 27% - by 20% NS---NSNS- by 36% -NS- by 25% - by 41% by 26% by 26% NS-NS-NS----
Simvastatincardiovascular prevention, in secondary prevention vs simvastatinNSNSNS-NSNSNS---NS- by 14% - by 1667% -NS-NSNS---NS------
Simvastatincardiovascular prevention, in diabetic patients vs placebo------------------------------
Simvastatinheart failure, in all type of patients vs control----NS-------NS-----------------
Simvastatinheart failure, in all type of patients vs placeboNS---NS-------------------------
Simvastatinheart failure, in all type of patients vs ezetimibe------------------------------

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons